Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.58 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.58 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.58 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | PYGB | P11216 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| B-D-Galactose SCHEMBL79550 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL10050862 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL10050865 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL77612 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL2446529 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL23758905 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| Dextrose SCHEMBL4757976 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL16550455 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL21123450 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL10050863 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321284-A1 | COMPOUND, CONTRAST AGENT, AND METHOD FOR PRODUCING COMPOUND | ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20170333568-A1 | GLYCOCONJUGATES AND METHODS FOR THEIR USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-11-23 | — | — | US | disclosed |
| WO-2017136739-A1 | GLUCOSE CONJUGATES OF TRIPTOLIDE, ANALOGS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-10 | — | — | WO | disclosed |
| US-9718850-B2 | Triterpene saponins, methods of synthesis and uses thereof | MEMORIAL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170007708-A1 | GLYCOTARGETING THERAPEUTICS | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2017-01-12 | — | — | US | disclosed |
| EP-2855536-B1 | NOVEL COMPOSITION FOR PREPARING POLYSACCHARIDE FIBERS | DU PONT (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160287620-A1 | GLYCOCLUSTERS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS | UNIVERSITE DE MONTPELLIER (FR) | 2016-10-06 | — | — | US | disclosed |
| US-20160139143-A1 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MEDICAL SYSTEMS, INC. | 2016-05-19 | — | — | US | disclosed |
| EP-2274017-B1 | E-SELECTIN SPECIFIC VASCULAR DELIVERY SYSTEMS | UNIV BEN GURION (IL) | 2016-04-13 | — | — | EP | disclosed |
| US-9211250-B2 | Heterogeneous polymeric micelles for intracellular delivery | UNIVERSITY OF WASHINGTON (US) | 2015-12-15 | — | — | US | disclosed |
| US-20130214443-A1 | PROCESS FOR THE PRODUCTION OF CARBON FIBERS FROM POLY(ALPHA(1->3) GLUCAN) FIBERS | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-08-22 | — | — | US | disclosed |
| US-8513394-B2 | Saccharide fluorescent substrates, preparation method and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2013-08-20 | — | — | US | disclosed |
| US-20130130936-A1 | Method of Conducting an Assay | ADVANCED LIQUID LOGIC, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013052730-A1 | NOVEL COMPOSITION FOR PREPARING POLYSACCHARIDE FIBERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-11 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| US-8093062-B2 | Enzymatic assays using umbelliferone substrates with cyclodextrins in droplets in oil | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-01-10 | — | — | US | disclosed |
| US-20110118132-A1 | Enzymatic Assays Using Umbelliferone Substrates with Cyclodextrins in Droplets of Oil | ADVANCED LIQUID LOGIC, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7521568-B2 | Enantiopure 4-deoxypentenosides, dihydropyrans and tetrahydropyrans and syntheses thereof | PURDUE RESEARCH FOUNDATION (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521568-B2 | Enantiopure 4-deoxypentenosides, dihydropyrans and tetrahydropyrans and syntheses thereof | PURDUE RESEARCH FOUNDATION (US) | 2009-04-21 | — | — | US | disclosed |
| EP-2033663-A1 | Saccharidic fluorescent substrates, method of preparing same and use of same | Commissariat à l'Energie Atomique (FR) | 2009-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287620-A1 | GLYCOCLUSTERS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS | GALE, MGAM, GALK1 | LGALS3 41/4885LGALS1 34/4885LGALS9 72/4885 |
| US-20170007708-A1 | GLYCOTARGETING THERAPEUTICS | CD74, LGALS1, LY96 | LGALS3 4/4885LGALS1 2/4885LGALS9 29/4885 |
| US-20170333568-A1 | GLYCOCONJUGATES AND METHODS FOR THEIR USE | B3GAT3, LGALS3, GALNT3 | LGALS3 2/4885LGALS1 8/4885LGALS9 27/4885 |
| US-20230321284-A1 | COMPOUND, CONTRAST AGENT, AND METHOD FOR PRODUCING COMPOUND | RXFP1, AVPR2, RXFP3 | LGALS3 1349/4885LGALS1 815/4885LGALS9 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.